{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:33:07Z","timestamp":1709685187383},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,4]]},"DOI":"10.7759\/cureus.55528","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T06:14:55Z","timestamp":1709619295000},"source":"Crossref","is-referenced-by-count":0,"title":["Fibrodysplasia Ossificans Progressiva: A Case Report"],"prefix":"10.7759","author":[{"given":"Linzeng","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongyuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000802","article-title":"Fibrodysplasia ossificans progressiva: lessons learned from a rare disease","volume":"31","author":"Akyuz G","year":"2019","unstructured":"Akyuz G, Gencer-Atalay K, Ata P. Fibrodysplasia ossificans progressiva: lessons learned from a rare disease. Curr Opin Pediatr. 2019, 31:716-22. 10.1097\/MOP.0000000000000802","journal-title":"Curr Opin Pediatr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13777","article-title":"Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP)","volume":"85","author":"Hsiao EC","year":"2019","unstructured":"Hsiao EC, Di Rocco M, Cali A, et al.. Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP). Br J Clin Pharmacol. 2019, 85:1199-207. 10.1111\/bcp.13777","journal-title":"Br J Clin Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.I.00705","article-title":"Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva","volume":"92","author":"Kaplan FS","year":"2010","unstructured":"Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010, 92:686-91. 10.2106\/JBJS.I.00705","journal-title":"J Bone Joint Surg Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1517\/21678707.2013.825208","article-title":"From mysteries to medicines: drug development for fibrodysplasia ossificans progressive","volume":"1","author":"Kaplan FS","year":"2013","unstructured":"Kaplan FS, Pignolo RJ, Shore EM. From mysteries to medicines: drug development for fibrodysplasia ossificans progressive. Expert Opin Orphan Drugs. 2013, 1:637-49. 10.1517\/21678707.2013.825208","journal-title":"Expert Opin Orphan Drugs"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.33314\/jnhrc.v16i2.1193","article-title":"Fibrodysplasia ossificans progressiva: a case report","volume":"16","author":"Acharya S","year":"2018","unstructured":"Acharya S, Joshi S, Chaulagain R. Fibrodysplasia ossificans progressiva: a case report. J Nepal Health Res Counc. 2018, 16:245-7.","journal-title":"J Nepal Health Res Counc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ng1783","article-title":"A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva","volume":"38","author":"Shore EM","year":"2006","unstructured":"Shore EM, Xu M, Feldman GJ, et al.. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006, 38:525-7. 10.1038\/ng1783","journal-title":"Nat Genet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2018.03.007","article-title":"Acquired and congenital forms of heterotopic ossification: new pathogenic insights and therapeutic opportunities","volume":"40","author":"Pacifici M","year":"2018","unstructured":"Pacifici M. Acquired and congenital forms of heterotopic ossification: new pathogenic insights and therapeutic opportunities. Curr Opin Pharmacol. 2018, 40:51-8. 10.1016\/j.coph.2018.03.007","journal-title":"Curr Opin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/ijabmr.IJABMR_52_18","article-title":"Feasibility of bisphosphonate therapy in an Indian pediatric patient of fibrodysplasia ossificans progressiva","volume":"9","author":"Kochar IS","year":"2019","unstructured":"Kochar IS, Sethi A, Ramachandran S. Feasibility of bisphosphonate therapy in an Indian pediatric patient of fibrodysplasia ossificans progressiva. Int J Appl Basic Med Res. 2019, 9:118-20. 10.4103\/ijabmr.IJABMR_52_18","journal-title":"Int J Appl Basic Med Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1021\/cb300655w","article-title":"Development of an ALK2-biased BMP type I receptor kinase inhibitor","volume":"8","author":"Mohedas AH","year":"2013","unstructured":"Mohedas AH, Xing X, Armstrong KA, Bullock AN, Cuny GD, Yu PB. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol. 2013, 8:1291-302. 10.1021\/cb300655w","journal-title":"ACS Chem Biol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-015-0104-z","article-title":"Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B","volume":"13","author":"Olsen OE","year":"2015","unstructured":"Olsen OE, Wader KF, Hella H, et al.. Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. Cell Commun Signal. 2015, 13:27. 10.1186\/s12964-015-0104-z","journal-title":"Cell Commun Signal"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1515397113","article-title":"Inhibition of Hif1\u03b1 prevents both trauma-induced and genetic heterotopic ossification","volume":"113","author":"Agarwal S","year":"2016","unstructured":"Agarwal S, Loder S, Brownley C, et al.. Inhibition of Hif1\u03b1 prevents both trauma-induced and genetic heterotopic ossification. Proc Natl Acad Sci USA. 2016, 113:E338-47. 10.1073\/pnas.1515397113","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42614","article-title":"Novel therapeutic targets for fibrodysplasia ossificans progressiva: emerging strategies and future directions","volume":"15","author":"Shaikh U","year":"2023","unstructured":"Shaikh U, Khan A, Kumari P, et al.. Novel therapeutic targets for fibrodysplasia ossificans progressiva: emerging strategies and future directions. Cureus. 2023, 15:e42614. 10.7759\/cureus.42614","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2334","article-title":"Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-\u03b3 agonists","volume":"17","author":"Shimono K","year":"2011","unstructured":"Shimono K, Tung WE, Macolino C, et al.. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-\u03b3 agonists. Nat Med. 2011, 17:454-60. 10.1038\/nm.2334","journal-title":"Nat Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041130","article-title":"Enhancing the effectiveness of oligonucleotide therapeutics using cell-penetrating peptide conjugation, chemical modification, and carrier-based delivery strategies","volume":"15","author":"Anwar S","year":"2023","unstructured":"Anwar S, Mir F, Yokota T. Enhancing the effectiveness of oligonucleotide therapeutics using cell-penetrating peptide conjugation, chemical modification, and carrier-based delivery strategies. Pharmaceutics. 2023, 15:10.3390\/pharmaceutics15041130","journal-title":"Pharmaceutics"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33956-9","article-title":"Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery","volume":"13","author":"Yang YS","year":"2022","unstructured":"Yang YS, Kim JM, Xie J, et al.. Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery. Nat Commun. 2022, 13:6175. 10.1038\/s41467-022-33956-9","journal-title":"Nat Commun"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4055\/cios.2018.10.3.271","article-title":"Mesenchymal stem cell therapy for bone regeneration","volume":"10","author":"Jin YZ","year":"2018","unstructured":"Jin YZ, Lee JH. Mesenchymal stem cell therapy for bone regeneration. Clin Orthop Surg. 2018, 10:271-8. 10.4055\/cios.2018.10.3.271","journal-title":"Clin Orthop Surg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/236245-fibrodysplasia-ossificans-progressiva-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T06:14:58Z","timestamp":1709619298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/236245-fibrodysplasia-ossificans-progressiva-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.55528","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,4]]}}}